Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
4003154 | American Journal of Ophthalmology | 2011 | 10 Pages |
Abstract
Compared with PK, DALK has a favorable cost-effectiveness ratio and, resources permitting, should be considered as a first-line treatment for keratoconus. Additional studies are needed to confirm the expected advantages of DALK over PK when it comes to long-term graft failure rates.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Timothy S. Koo, Eric Finkelstein, Donald Tan, Jodhbir S. Mehta,